MYRIAD GENETICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.66 USD | -2.76% |
|
+2.96% | +28.84% |
| 13/05 | Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating | MT |
| 08/05 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Presenter SpeechPaul Diaz (Executives)So we're really excited to have you all here today, and ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.
Calendar
16/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
25.36
USD
Average target price
25.09
USD
Spread / Average Target
-1.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.84% | 229.53Cr | |
| -4.62% | 1.22TCr | |
| +8.48% | 595.76Cr | |
| +28.39% | 545.49Cr | |
| -6.28% | 434.31Cr | |
| -52.84% | 317.95Cr | |
| +12.93% | 274.54Cr | |
| -3.80% | 227.88Cr | |
| -4.64% | 192.09Cr | |
| +2.20% | 161.05Cr |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Transcript : Myriad Genetics, Inc. - Analyst/Investor Day